共 50 条
- [21] Homologous Recombination Repair in Biliary Tract Cancers: A Prime Target for PARP Inhibition?CANCERS, 2022, 14 (10)Yin, Chao论文数: 0 引用数: 0 h-index: 0机构: Georgetown Univ, Lombardi Comprehens Canc Ctr, Ruesch Ctr Cure Gastrointestinal Canc, Washington, DC 20007 USA Georgetown Univ, Lombardi Comprehens Canc Ctr, Ruesch Ctr Cure Gastrointestinal Canc, Washington, DC 20007 USA论文数: 引用数: h-index:机构:Roy, Tina论文数: 0 引用数: 0 h-index: 0机构: Georgetown Univ, Lombardi Comprehens Canc Ctr, Ruesch Ctr Cure Gastrointestinal Canc, Washington, DC 20007 USA Georgetown Univ, Lombardi Comprehens Canc Ctr, Ruesch Ctr Cure Gastrointestinal Canc, Washington, DC 20007 USADecker, Brennan论文数: 0 引用数: 0 h-index: 0机构: Fdn Med, Cambridge, MA USA Georgetown Univ, Lombardi Comprehens Canc Ctr, Ruesch Ctr Cure Gastrointestinal Canc, Washington, DC 20007 USAAlexander, Sonja论文数: 0 引用数: 0 h-index: 0机构: Fdn Med, Cambridge, MA USA Georgetown Univ, Lombardi Comprehens Canc Ctr, Ruesch Ctr Cure Gastrointestinal Canc, Washington, DC 20007 USAMargolis, Mathew论文数: 0 引用数: 0 h-index: 0机构: Fdn Med, Cambridge, MA USA Georgetown Univ, Lombardi Comprehens Canc Ctr, Ruesch Ctr Cure Gastrointestinal Canc, Washington, DC 20007 USAJha, Reena C.论文数: 0 引用数: 0 h-index: 0机构: Georgetown Univ, Dept Radiol, Med Ctr, Washington, DC 20007 USA Georgetown Univ, Lombardi Comprehens Canc Ctr, Ruesch Ctr Cure Gastrointestinal Canc, Washington, DC 20007 USAKupfer, Gary M.论文数: 0 引用数: 0 h-index: 0机构: Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20007 USA Georgetown Univ, Lombardi Comprehens Canc Ctr, Ruesch Ctr Cure Gastrointestinal Canc, Washington, DC 20007 USAHe, Aiwu R.论文数: 0 引用数: 0 h-index: 0机构: Georgetown Univ, Lombardi Comprehens Canc Ctr, Ruesch Ctr Cure Gastrointestinal Canc, Washington, DC 20007 USA Georgetown Univ, Lombardi Comprehens Canc Ctr, Ruesch Ctr Cure Gastrointestinal Canc, Washington, DC 20007 USA
- [22] Exploring homologous recombination deficiency threshold for predicting response to PARP inhibitor in prostate cancerEUROPEAN UROLOGY, 2024, 85 : S1569 - S1569Wang, J.论文数: 0 引用数: 0 h-index: 0机构: Sun Yat Sen Univ Canc Ctr, Dept Urol, Guangzhou, Peoples R China Sun Yat Sen Univ Canc Ctr, Dept Urol, Guangzhou, Peoples R ChinaZhao, D.论文数: 0 引用数: 0 h-index: 0机构: Sun Yat Sen Univ Canc Ctr, Dept Urol, Guangzhou, Peoples R China Sun Yat Sen Univ Canc Ctr, Dept Urol, Guangzhou, Peoples R ChinaZhao, J.论文数: 0 引用数: 0 h-index: 0机构: Sun Yat Sen Univ Canc Ctr, Dept Urol, Guangzhou, Peoples R China Sun Yat Sen Univ Canc Ctr, Dept Urol, Guangzhou, Peoples R ChinaLi, Y.论文数: 0 引用数: 0 h-index: 0机构: Sun Yat Sen Univ Canc Ctr, Dept Urol, Guangzhou, Peoples R China Sun Yat Sen Univ Canc Ctr, Dept Urol, Guangzhou, Peoples R ChinaZhou, F.论文数: 0 引用数: 0 h-index: 0机构: Sun Yat Sen Univ Canc Ctr, Dept Urol, Guangzhou, Peoples R China Sun Yat Sen Univ Canc Ctr, Dept Urol, Guangzhou, Peoples R China
- [23] Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line LibrariesScientific Data, 11Shiro Takamatsu论文数: 0 引用数: 0 h-index: 0机构: Kyoto University Graduate School of Medicine,Department of Gynecology and ObstetricsKosuke Murakami论文数: 0 引用数: 0 h-index: 0机构: Kyoto University Graduate School of Medicine,Department of Gynecology and ObstetricsNoriomi Matsumura论文数: 0 引用数: 0 h-index: 0机构: Kyoto University Graduate School of Medicine,Department of Gynecology and Obstetrics
- [24] Exploring homologous recombination deficiency threshold for predicting response to PARP inhibitor in prostate cancerANNALS OF ONCOLOGY, 2023, 34 : S1577 - S1577Wang, J.论文数: 0 引用数: 0 h-index: 0机构: Sun Yat Sen Univ, Urol, Canc Ctr, Guangzhou, Peoples R China Sun Yat Sen Univ, Urol, Canc Ctr, Guangzhou, Peoples R ChinaZhao, D.论文数: 0 引用数: 0 h-index: 0机构: Sun Yat Sen Univ, Urol, Canc Ctr, Guangzhou, Peoples R China Sun Yat Sen Univ, Urol, Canc Ctr, Guangzhou, Peoples R ChinaZhao, Y.论文数: 0 引用数: 0 h-index: 0机构: Precis Sci Beijing Co Ltd, Sci Invest, Beijing, Peoples R China Sun Yat Sen Univ, Urol, Canc Ctr, Guangzhou, Peoples R ChinaLi, Y.论文数: 0 引用数: 0 h-index: 0机构: Sun Yat Sen Univ, Urol, Canc Ctr, Guangzhou, Peoples R China Sun Yat Sen Univ, Urol, Canc Ctr, Guangzhou, Peoples R ChinaZhou, F.论文数: 0 引用数: 0 h-index: 0机构: Sun Yat Sen Univ, Urol, Canc Ctr, Guangzhou, Peoples R China Sun Yat Sen Univ, Urol, Canc Ctr, Guangzhou, Peoples R China
- [25] Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line LibrariesSCIENTIFIC DATA, 2024, 11 (01)Takamatsu, Shiro论文数: 0 引用数: 0 h-index: 0机构: Kyoto Univ, Grad Sch Med, Dept Gynecol & Obstet, Kyoto, Kyoto, Japan Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX USA Kyoto Univ, Grad Sch Med, Dept Gynecol & Obstet, Kyoto, Kyoto, JapanMurakami, Kosuke论文数: 0 引用数: 0 h-index: 0机构: Kindai Univ, Fac Med, Dept Obstet & Gynecol, Osakasayama, Osaka, Japan Johns Hopkins Univ, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD USA Kyoto Univ, Grad Sch Med, Dept Gynecol & Obstet, Kyoto, Kyoto, JapanMatsumura, Noriomi论文数: 0 引用数: 0 h-index: 0机构: Kindai Univ, Fac Med, Dept Obstet & Gynecol, Osakasayama, Osaka, Japan Kyoto Univ, Grad Sch Med, Dept Gynecol & Obstet, Kyoto, Kyoto, Japan
- [26] Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP InhibitorsONCOTARGETS AND THERAPY, 2022, 15 : 1105 - 1117Miller, Rowan E.论文数: 0 引用数: 0 h-index: 0机构: Univ Coll London Hosp, Dept Med Oncol, London, England St Bartholomews Hosp, Dept Med Oncol, London, England Univ Coll London Hosp, Dept Med Oncol, London, EnglandElyashiv, Osnat论文数: 0 引用数: 0 h-index: 0机构: Univ Coll London Hosp, Dept Med Oncol, London, England Univ Coll London Hosp, Dept Med Oncol, London, EnglandEl-Shakankery, Karim H.论文数: 0 引用数: 0 h-index: 0机构: Univ Coll London Hosp, Dept Med Oncol, London, England Univ Coll London Hosp, Dept Med Oncol, London, EnglandLedermann, Jonathan A.论文数: 0 引用数: 0 h-index: 0机构: Univ Coll London Hosp, Dept Med Oncol, London, England UCL, UCL Canc Inst, London, England UCL Canc Inst, 72 Huntley St, London WC1E 6DD, England Univ Coll London Hosp, Dept Med Oncol, London, England
- [27] KRAS pharmacological blockade elicits tumoral homologous recombination deficiency exploitable with PARP inhibitorsEUROPEAN JOURNAL OF CANCER, 2024, 211 : S92 - S93Welch, C.论文数: 0 引用数: 0 h-index: 0机构: FIMA, Canc Ctr, Ctr Appl Med Res CIMA, Pamplona, Spain FIMA, Canc Ctr, Ctr Appl Med Res CIMA, Pamplona, SpainNovoa, G.论文数: 0 引用数: 0 h-index: 0机构: FIMA, Canc Ctr, Ctr Appl Med Res CIMA, Pamplona, Spain FIMA, Canc Ctr, Ctr Appl Med Res CIMA, Pamplona, SpainLlorente Llorente, S.论文数: 0 引用数: 0 h-index: 0机构: VHIO, Noncolorectal GI Canc Translat Res Grp, Barcelona, Spain FIMA, Canc Ctr, Ctr Appl Med Res CIMA, Pamplona, SpainSantos Ramos, A.论文数: 0 引用数: 0 h-index: 0机构: CNIO, Lung Canc Clin Res Unit, Madrid, Spain FIMA, Canc Ctr, Ctr Appl Med Res CIMA, Pamplona, SpainSogari, A.论文数: 0 引用数: 0 h-index: 0机构: Univ Turin, Dept Oncol, Turin, Italy FIMA, Canc Ctr, Ctr Appl Med Res CIMA, Pamplona, SpainFernandez Lagos, A.论文数: 0 引用数: 0 h-index: 0机构: FIMA, Canc Ctr, Ctr Appl Med Res CIMA, Pamplona, Spain FIMA, Canc Ctr, Ctr Appl Med Res CIMA, Pamplona, SpainFileu, I.论文数: 0 引用数: 0 h-index: 0机构: FIMA, Canc Ctr, Ctr Appl Med Res CIMA, Pamplona, Spain FIMA, Canc Ctr, Ctr Appl Med Res CIMA, Pamplona, SpainGuruceaga, E.论文数: 0 引用数: 0 h-index: 0机构: FIMA, Bioinformat Core, Ctr Appl Med Res CIMA, Pamplona, Spain FIMA, Canc Ctr, Ctr Appl Med Res CIMA, Pamplona, SpainCalvo, A.论文数: 0 引用数: 0 h-index: 0机构: FIMA, Canc Ctr, Ctr Appl Med Res CIMA, Pamplona, Spain FIMA, Canc Ctr, Ctr Appl Med Res CIMA, Pamplona, SpainBakartxo Otegui, N.论文数: 0 引用数: 0 h-index: 0机构: FIMA, Canc Ctr, Ctr Appl Med Res CIMA, Pamplona, Spain FIMA, Canc Ctr, Ctr Appl Med Res CIMA, Pamplona, SpainBattuello, P.论文数: 0 引用数: 0 h-index: 0机构: Univ Turin, Dept Oncol, Turin, Italy FIMA, Canc Ctr, Ctr Appl Med Res CIMA, Pamplona, SpainCrisafulli, G.论文数: 0 引用数: 0 h-index: 0机构: Univ Turin, Dept Oncol, Turin, Italy FIMA, Canc Ctr, Ctr Appl Med Res CIMA, Pamplona, SpainAmbrogio, C.论文数: 0 引用数: 0 h-index: 0机构: Univ Turin, Mol Biotechnol Ctr, Turin, Italy FIMA, Canc Ctr, Ctr Appl Med Res CIMA, Pamplona, SpainSantamaria, D.论文数: 0 引用数: 0 h-index: 0机构: Ctr Invest Canc CIC CSIC, Dept Oncol, Salamanca, Spain FIMA, Canc Ctr, Ctr Appl Med Res CIMA, Pamplona, SpainBardelli, A.论文数: 0 引用数: 0 h-index: 0机构: Univ Turin, Dept Oncol, Turin, Italy FIMA, Canc Ctr, Ctr Appl Med Res CIMA, Pamplona, SpainTian, T.论文数: 0 引用数: 0 h-index: 0机构: VHIO, Noncolorectal GI Canc Translat Res Grp, Barcelona, Spain FIMA, Canc Ctr, Ctr Appl Med Res CIMA, Pamplona, SpainFerrer, I.论文数: 0 引用数: 0 h-index: 0机构: CNIO, Lung Canc Clin Res Unit, Madrid, Spain FIMA, Canc Ctr, Ctr Appl Med Res CIMA, Pamplona, SpainRusso, M.论文数: 0 引用数: 0 h-index: 0机构: Univ Turin, Dept Oncol, Turin, Italy FIMA, Canc Ctr, Ctr Appl Med Res CIMA, Pamplona, SpainVicent, S.论文数: 0 引用数: 0 h-index: 0机构: FIMA, Canc Ctr, Ctr Appl Med Res CIMA, Pamplona, Spain FIMA, Canc Ctr, Ctr Appl Med Res CIMA, Pamplona, Spain
- [28] Use of homologous recombination deficiency (HRD) score to enrich for niraparib sensitive high grade ovarian tumors.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Wilcoxen, Keith Matthew论文数: 0 引用数: 0 h-index: 0机构: TESARO Inc, Waltham, MA USABecker, Marc论文数: 0 引用数: 0 h-index: 0机构: TESARO Inc, Waltham, MA USANeff, Christopher论文数: 0 引用数: 0 h-index: 0机构: TESARO Inc, Waltham, MA USAAbkevich, Victor论文数: 0 引用数: 0 h-index: 0机构: TESARO Inc, Waltham, MA USAJones, Joshua Timothy论文数: 0 引用数: 0 h-index: 0机构: TESARO Inc, Waltham, MA USAHou, Xiaonan论文数: 0 引用数: 0 h-index: 0机构: TESARO Inc, Waltham, MA USAWang, Yan论文数: 0 引用数: 0 h-index: 0机构: TESARO Inc, Waltham, MA USAHartman, Anne-Renee论文数: 0 引用数: 0 h-index: 0机构: TESARO Inc, Waltham, MA USAAlHilli, Mariam M.论文数: 0 引用数: 0 h-index: 0机构: TESARO Inc, Waltham, MA USAGutin, Alexander论文数: 0 引用数: 0 h-index: 0机构: TESARO Inc, Waltham, MA USAAgarwal, Shefali论文数: 0 引用数: 0 h-index: 0机构: TESARO Inc, Waltham, MA USATimms, Kirsten论文数: 0 引用数: 0 h-index: 0机构: TESARO Inc, Waltham, MA USAHaluska, Paul论文数: 0 引用数: 0 h-index: 0机构: TESARO Inc, Waltham, MA USA
- [29] Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitorsEMBO MOLECULAR MEDICINE, 2020, 12 (06)Lahiguera, Alvaro论文数: 0 引用数: 0 h-index: 0机构: Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, Spain Inst Invest Biomed Bellvitge IDIBELL, Oncobell Program, Barcelona, Spain Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, SpainHyrossova, Petra论文数: 0 引用数: 0 h-index: 0机构: Univ Barcelona, Dept Ciencies Fisiol, Barcelona, Spain Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, SpainFigueras, Agnes论文数: 0 引用数: 0 h-index: 0机构: Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, Spain Inst Invest Biomed Bellvitge IDIBELL, Oncobell Program, Barcelona, Spain Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, SpainGarzon, Diana论文数: 0 引用数: 0 h-index: 0机构: Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, Spain Inst Invest Biomed Bellvitge IDIBELL, Oncobell Program, Barcelona, Spain Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, SpainMoreno, Roger论文数: 0 引用数: 0 h-index: 0机构: Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, Spain Inst Invest Biomed Bellvitge IDIBELL, Oncobell Program, Barcelona, Spain Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, SpainSoto-Cerrato, Vanessa论文数: 0 引用数: 0 h-index: 0机构: Univ Barcelona, Dept Patol & Terapeut Expt, Barcelona, Spain Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, SpainMcNeish, Iain论文数: 0 引用数: 0 h-index: 0机构: Imperial Coll, Dept Surg & Canc, London, England Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, SpainSerra, Violeta论文数: 0 引用数: 0 h-index: 0机构: Vall dHebron Inst Oncol, Expt Therapeut Grp, Barcelona, Spain Inst Salud Carlos III, CIBERONC, Madrid, Spain Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, SpainLazaro, Conxi论文数: 0 引用数: 0 h-index: 0机构: Inst Invest Biomed Bellvitge IDIBELL, Oncobell Program, Barcelona, Spain Inst Salud Carlos III, CIBERONC, Madrid, Spain Hosp Duran i Reynals, Inst Catala Oncol, Hereditary Canc Program, Barcelona, Spain Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, SpainBarretina, Pilar论文数: 0 引用数: 0 h-index: 0机构: IDIBGI, Med Oncol Dept, Inst Catala Oncol, Girona, Spain Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, SpainBrunet, Joan论文数: 0 引用数: 0 h-index: 0机构: Inst Salud Carlos III, CIBERONC, Madrid, Spain Hosp Duran i Reynals, Inst Catala Oncol, Hereditary Canc Program, Barcelona, Spain IDIBGI, Inst Catala Oncol, Hereditary Canc Program, Girona, Spain Univ Girona, Sch Med, Med Sci Dept, Girona, Spain Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, SpainMenendez, Javier论文数: 0 引用数: 0 h-index: 0机构: Catalan Inst Oncol, Metab & Canc Grp, Program Canc Therapeut Resistance ProCURE, Girona, Spain Girona Biomed Res Inst IDIBGI, Girona, Spain Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, SpainMatias-Guiu, Xavier论文数: 0 引用数: 0 h-index: 0机构: Inst Invest Biomed Bellvitge IDIBELL, Oncobell Program, Barcelona, Spain Inst Salud Carlos III, CIBERONC, Madrid, Spain Hosp Univ Bellvitge, Servei Anat Patol, Barcelona, Spain Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, SpainVidal, August论文数: 0 引用数: 0 h-index: 0机构: Inst Invest Biomed Bellvitge IDIBELL, Oncobell Program, Barcelona, Spain Univ Barcelona, Dept Patol & Terapeut Expt, Barcelona, Spain Hosp Univ Bellvitge, Servei Anat Patol, Barcelona, Spain Xenopat, Carrer De La Feixa Llarga S-N, Barcelona, Spain Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, SpainVillanueva, Alberto论文数: 0 引用数: 0 h-index: 0机构: Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, Spain Inst Invest Biomed Bellvitge IDIBELL, Oncobell Program, Barcelona, Spain Xenopat, Carrer De La Feixa Llarga S-N, Barcelona, Spain Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, SpainTaylor-Harding, Barbie论文数: 0 引用数: 0 h-index: 0机构: Cedars Sinai Med Ctr, Womens Canc Program, Los Angeles, CA 90048 USA Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, SpainTanaka, Hisashi论文数: 0 引用数: 0 h-index: 0机构: Cedars Sinai Med Ctr, Womens Canc Program, Los Angeles, CA 90048 USA Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, SpainOrsulic, Sandra论文数: 0 引用数: 0 h-index: 0机构: Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, SpainJunza, Alexandra论文数: 0 引用数: 0 h-index: 0机构: Univ Rovira & Virgili, Dept Elect Engn DEEEA, Metabol Platform, Tarragona, Spain Biomed Res Ctr Diabet & Associated Metab Disorder, Madrid, Spain Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, SpainYanes, Oscar论文数: 0 引用数: 0 h-index: 0机构: Univ Rovira & Virgili, Dept Elect Engn DEEEA, Metabol Platform, Tarragona, Spain Biomed Res Ctr Diabet & Associated Metab Disorder, Madrid, Spain Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, SpainMunoz-Pinedo, Cristina论文数: 0 引用数: 0 h-index: 0机构: Bellvitge Biomed Res Inst IDIBELL, Oncobell Program, Cell Death Regulat Grp, Barcelona, Spain Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, SpainPalomero, Luis论文数: 0 引用数: 0 h-index: 0机构: Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, Spain Inst Invest Biomed Bellvitge IDIBELL, Oncobell Program, Barcelona, Spain Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, SpainAngel Pujana, Miquel论文数: 0 引用数: 0 h-index: 0机构: Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, Spain Inst Invest Biomed Bellvitge IDIBELL, Oncobell Program, Barcelona, Spain Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, SpainCarlos Perales, Jose论文数: 0 引用数: 0 h-index: 0机构: Univ Barcelona, Dept Ciencies Fisiol, Barcelona, Spain Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, SpainVinals, Francesc论文数: 0 引用数: 0 h-index: 0机构: Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, Spain Inst Invest Biomed Bellvitge IDIBELL, Oncobell Program, Barcelona, Spain Univ Barcelona, Dept Ciencies Fisiol, Barcelona, Spain Hosp Duran i Reynals, Inst Catala Oncol, Program Canc Therapeut Resistance ProCURE, Barcelona, Spain
- [30] Translational relevance of the combined treatment PARP inhibitors and AsiDNA in homologous recombination proficient tumorsANNALS OF ONCOLOGY, 2022, 33 : S4 - S4Jdey, W.论文数: 0 引用数: 0 h-index: 0机构: Onxeo, R&D Dept, Paris, France Onxeo, R&D Dept, Paris, FranceTrochon-Joseph, V.论文数: 0 引用数: 0 h-index: 0机构: Onxeo, R&D Dept, Paris, France Onxeo, R&D Dept, Paris, FranceDoizelet, C.论文数: 0 引用数: 0 h-index: 0机构: Onxeo, R&D Dept, Paris, France Onxeo, R&D Dept, Paris, FranceHayes, V.论文数: 0 引用数: 0 h-index: 0机构: Onxeo, R&D Dept, Paris, France Onxeo, R&D Dept, Paris, FranceCohendet, A.论文数: 0 引用数: 0 h-index: 0机构: Onxeo, R&D Dept, Paris, France Onxeo, R&D Dept, Paris, FranceLienafa, M-C.论文数: 0 引用数: 0 h-index: 0机构: Onxeo, R&D Dept, Paris, France Onxeo, R&D Dept, Paris, FranceZandanel, C.论文数: 0 引用数: 0 h-index: 0机构: Onxeo, R&D Dept, Paris, France Onxeo, R&D Dept, Paris, FranceDe Beaumont, O.论文数: 0 引用数: 0 h-index: 0机构: Onxeo, R&D Dept, Paris, France Onxeo, R&D Dept, Paris, FranceMiara, J.论文数: 0 引用数: 0 h-index: 0机构: Onxeo, Paris, France Onxeo, R&D Dept, Paris, France